Pfizer, Celgene and Baxter were among the investors in the cancer drug developer's latest round, boosting its funding to $93m in total.
US-based oncology-focused biopharmaceutical company Mirna Therapeutics secured $41.8m yesterday for a series D round led by healthcare company Baxter’s corporate venturing arm, Baxter Ventures.
The round also included pharmaceutical firms Celgene and Pfizer, which invested through its Pfizer Ventures subsidiary, as well as Eastern Capital, Santé Ventures, Morningside Ventures, Rock Springs Capital, Sofinnova Ventures, New Enterprise Associates (NEA), Osage University Partners and Correlation Ventures.
Mirna will use the funding to advance its lead drug candidate, a cancer compound, into Phase…
